Renaissance Capital logo

CING News

ADHD drug developer Cingulate prices IPO at $6, the low end of the downwardly revised range

Cingulate logo

Cingulate, a Phase 3-ready biotech developing formulations of stimulant drugs for ADHD, raised $25 million by offering 4.2 million units at $6, the low end of the downwardly revised range of $6 to $8. The company offered 0.6 million more units than anticipated....read more

ADHD drug developer Cingulate further lowers deal size by 38% ahead of $25 million IPO

Cingulate logo

Cingulate, a Phase 3-ready biotech developing formulations of stimulant drugs for ADHD, lowered the proposed deal size for its upcoming IPO on Wednesday. In its latest filing, the company also disclosed financials for the 9mo21 and replaced...read more

ADHD drug developer Cingulate lowers deal size by 20% ahead of $40 million IPO

Cingulate logo

Cingulate, a Phase 3-ready biotech developing formulations of stimulant drugs for ADHD, lowered the proposed deal size for its upcoming IPO on Tuesday. The Kansas City, KS-based company now plans to raise $40 million by offering 4.4 million shares at a price...read more

US IPO Week Ahead: Software, payments, telecom towers, and more in an 8 IPO week

GTLB

The Fall IPO market is expected to stay busy with eight IPOs schedule to raise $1.9 billion in the week ahead. Software development platform GitLab (GTLB) plans to raise $598 million at a $9.4 billion market cap. This founder-led company...read more